A present study was conducted to investigate compatibility of β-blocker drugs( like atenolol, labetalol hydrochloride, bisoprolol fumarate, metoprolol succinate, carvedilol and propranolol hydrochloride) with the pharmaceutical excipient povidone. To check the influence of peroxide impurity present in povidone on the stability of β-blockers, a binary mixture technique has been adopted. The binary mixtures (1:1) of β-blockers with povidone excipient were stored for the duration of 6 months at accelerated conditions (40°C and 75% RH) and analyzed with the technique of high-performance liquid chromatography (HPLC). On analysis, HPLC results shows that, the percentage of total impurity for atenolol-2.15%, bisoprolol fumarate-3.55%, carvedilol-2.19%, and labetalol hydrochloride-1.89%, with respect to povidone. To verify the interaction of HO present in povidone as an impurity, oxidative degradation of selected active pharmaceutical ingredients were performed and degradation profile were compared with that of degradation impurities generated in drug-excipient mixture at accelerated conditions. The relative retention time (RRT) of impurities generated in accelerated stability study samples resembles the RRT of degradation products generated by oxidative degradation of pure drugs. Thus, it confirms that degradation of β-blockers with povidone was mediated by organic peroxides present as an impurity in povidone.
Parenteral suspensions of poorly water-soluble salts for intramuscular administration retain therapeutic drug concentration over a long duration. In vitro drug dissolution testing is a prerequisite to assess batch-to-batch variability as well as to assure appropriate drug release during formulation development. The purpose of the present work was to compare the drug release kinetics of two salts of pramipexole in powdered and suspension forms. The two salts employed for the dissolution study were commercially available soluble salt-pramipexole dihydrochloride monohydrate (PRP HCl) and in-house synthesized poorly water-soluble salt, pramipexole pamoic acid salt (PRP PAM). Modified USP apparatus 2 (paddle) using dialysis sac and open loop USP apparatus 4 (flow-through cell) were used for the in vitro dissolution studies. The drug release was estimated using high-performance liquid chromatography. The release kinetics were statistically analyzed using various mathematical models. Results obtained from in vitro dissolution testing showed an immediate-release profile for PRP HCl and a sustained-release profile for PRP PAM, indicating its long-acting potential. The developed method could discriminate between different particle sizes of the PRP PAM salt. The results indicated that the release profile of the PRP PAM salt using modified USP apparatus 2 with dialysis sac more closely mimicked the desired in vivo conditions of intramuscular administration as compared to open loop USP apparatus 4. The developed dissolution method can be used as a quality control tool for PRP PAM injectable suspension.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.